Skip to content

Processa Pharmaceuticals, Inc.

PCSA

CIK 0001533743

← back to feed
Revenue (TTM)
$0
Q1 May 2026
Net Income (TTM)
−$13.58M
−14.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$9.19
+89.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$10.51M
Q1 May 2026
Cash
$1.69M
Q1 May 2026
Total Debt
$257.51K
Q1 May 2026
Shares Outstanding
2.75M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings